(Q54542037)

31 May 2018

title

Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma. (English)

1 reference

31 May 2018

1 reference

angiogenesis inhibitor

1 reference

1

1 reference

31 May 2018

Peter Igaz

2

1 reference

31 May 2018

Laurence Amar

4

1 reference

31 May 2018

Rossella Libé

object named as

Rossella Libé

Anne-Paule Gimenez-Roqueplo

5

0 references

object named as

Anne-Paule Gimenez-Roqueplo

11

0 references

Xavier Jeunemaitre

10

object named as

Xavier Jeunemaitre

1 reference

31 May 2018

Nelly Burnichon

3

1 reference

31 May 2018

Cécile Badoual

6

1 reference

31 May 2018

Frédérique Tissier

7

1 reference

31 May 2018

Jérôme Bertherat

8

1 reference

31 May 2018

Pierre-François Plouin

9

1 reference

31 May 2018

publication date

1 March 2012

1 reference

31 May 2018

published in

Endocrine Pathology

1 reference

31 May 2018

volume

23

1 reference

31 May 2018

issue

1

1 reference

31 May 2018

page(s)

34-42

1 reference

31 May 2018

https://scigraph.springernature.com/pub.10.1007/s12022-011-9189-0

exact match

0 references

cites work

Recent advances in the genetics of phaeochromocytoma and functional paraganglioma

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Identification of the von Hippel-Lindau disease tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

SDHA is a tumor suppressor gene causing paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Mutations in SDHC cause autosomal dominant paraganglioma, type 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Germline mutations in TMEM127 confer susceptibility to pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

The diagnosis and management of malignant phaeochromocytoma and paraganglioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

The significance of angiogenesis in malignant pheochromocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Pheochromocytomas: the (pseudo)-hypoxia hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Initial work-up and long-term follow-up in patients with phaeochromocytomas and paragangliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Cloning and expression pattern of EPAS1 in the chicken embryo. Colocalization with tyrosine hydroxylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

The Warburg effect is genetically determined in inherited pheochromocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Biomarkers of response and resistance to antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Succinate Dehydrogenase B Gene Mutations Predict Survival in Patients with Malignant Pheochromocytomas or Paragangliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-011-9189-0

Tumour angiogenesis and Ki-67 expression in phaeochromocytoma

21 January 2018

1 reference

12 December 2020

Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours

1 reference

12 December 2020

VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome

1 reference

12 December 2020

Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.

1 reference

12 December 2020

Predictive factors for malignant pheochromocytoma: analysis of 136 patients

1 reference

12 December 2020

Tumor angiogenesis in pheochromocytomas and paragangliomas

1 reference

12 December 2020

A report of succinate dehydrogenase B deficiency associated with metastatic papillary renal cell carcinoma: successful treatment with the multi-targeted tyrosine kinase inhibitor sunitinib

1 reference

12 December 2020

VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors

1 reference

12 December 2020

10.1007/S12022-011-9189-0

Identifiers

DOI

1 reference

31 May 2018

PubMed ID

22183643

1 reference

31 May 2018